Takahashi K, Okawa M, Matsumoto M, Mishima K, Yamadera H, Sasaki M, Ishizuka Y, Yamada K, Higuchi T, Okamoto N, Furuta H, Nakagawa H, Ohta T, Kuroda K, Sugita Y, Inoue Y, Uchimura N, Nagayama H, Miike T, Kamei K
National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
Psychiatry Clin Neurosci. 1999 Apr;53(2):211-3. doi: 10.1046/j.1440-1819.1999.00534.x.
The therapeutic effect of methylcobalamin (Met-12) on sleep-wake rhythm disorders was examined in a double-blind test. In the test group which was given a large dosage, a higher percentage of improvement was found compared to the control group with a small dosage, although the difference was not significant. The test group inconsistently showed significant improvement in both the sleep-wake cycle parameters and in clinical symptoms. The tendency was for the results to show a beneficial effect of Met-12 on rhythm disorders. However, because the percentage of improvement was low and significant improvement was inconsistent, Met-12 might be considered to have a low therapeutic potency and possible use as a booster for other treatment methods of the disorders.